Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:00am, Monday, 14'th Apr 2025
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?
10:15am, Thursday, 10'th Apr 2025
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Thursday, 03'rd Apr 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Organon (OGN) Could Beat Earnings Estimates Again
01:15pm, Wednesday, 02'nd Apr 2025
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
10:00am, Tuesday, 01'st Apr 2025
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
06:00am, Friday, 28'th Mar 2025
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
07:05pm, Thursday, 27'th Mar 2025
Organon (OGN) closed the most recent trading day at $14.56, moving -1.02% from the previous trading session.
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
06:55pm, Friday, 21'st Mar 2025
In the closing of the recent trading day, Organon (OGN) stood at $15.39, denoting a -1.35% change from the preceding trading day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:05am, Wednesday, 19'th Mar 2025
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Advances While Market Declines: Some Information for Investors
07:06pm, Tuesday, 18'th Mar 2025
Organon (OGN) concluded the recent trading session at $15.70, signifying a +0.51% move from its prior day's close.
Why Organon Is A Top Pick For Income Investors
10:58pm, Monday, 17'th Mar 2025
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three mont
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-
High-Yield Healthcare: 3 Stocks With Strong Dividends
07:16am, Sunday, 16'th Feb 2025
When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
12:47pm, Thursday, 13'th Feb 2025
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Wa
